Collectively, this positions the loss of hepatic CEACAM1 expression (and its resulting hyperinsulinemia and insulin resistance) on the crossroad of the pathogenesis of NAFLD and obesity. This evidence concerns the gene CEACAM1 and metabolic dysfunction-associated steatotic liver disease.